Urethritis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 20: Line 20:
| style="padding: 7px 7px; background: #DCDCDC;" |'''Nongonococcal Urethritis'''
| style="padding: 7px 7px; background: #DCDCDC;" |'''Nongonococcal Urethritis'''
| style="padding: 7px 7px; background: #F5F5DC;" |Preferred:  
| style="padding: 7px 7px; background: #F5F5DC;" |Preferred:  
::::[[Azithromycin]] 1 g PO in a single dose           
:::::[[Azithromycin]] 1 g PO in a single dose           
::::::::'''OR'''
:::::::::'''OR'''
::::[[Doxycycline]] 100 mg PO bid for 7 days
:::::[[Doxycycline]] 100 mg PO bid for 7 days
Alternatives:
Alternatives:
::::[[Erythromycin]] base 500 mg PO qid for 7 days
:::::[[Erythromycin]] base 500 mg PO qid for 7 days
::::[[Erythromycin ethylsuccinate]] 800 mg PO qid for 7 days
:::::[[Erythromycin ethylsuccinate]] 800 mg PO qid for 7 days
::::[[Levofloxacin]] 500 mg PO qd for 7 days  
:::::[[Levofloxacin]] 500 mg PO qd for 7 days  
::::[[Ofloxacin]] 300 mg PO bid for 7 days
:::::[[Ofloxacin]] 300 mg PO bid for 7 days
|-
|-
| style="padding: 7px 7px; background: #DCDCDC;" | '''Gonococcal Urethritis'''
| style="padding: 7px 7px; background: #DCDCDC;" | '''Gonococcal Urethritis'''
| style="padding: 7px 7px; background: #F5F5DC;" |Preferred:
| style="padding: 7px 7px; background: #F5F5DC;" |Preferred:
::::[[Ceftriaxone]] 250 mg IM in a single dose
:::::[[Ceftriaxone]] 250 mg IM in a single dose
::::::::'''PLUS'''
:::::::::'''PLUS'''
::::[[Azithromycin]] 1 g PO in a single dose
:::::[[Azithromycin]] 1 g PO in a single dose
Alternative:
Alternative:
::::[[Cefixime]] 400 mg PO in a single dose
:::::[[Cefixime]] 400 mg PO in a single dose
::::::::'''PLUS'''
:::::::::'''PLUS'''
::::[[Azithromycin]] 1 g PO in a single dose
:::::[[Azithromycin]] 1 g PO in a single dose
|-
|-
| style="padding: 7px 7px; background: #DCDCDC;" | '''Recurrent and Persistent Urethritis'''
| style="padding: 7px 7px; background: #DCDCDC;" | '''Recurrent and Persistent Urethritis'''
| style="padding: 7px 7px; background: #F5F5DC;" |
| style="padding: 7px 7px; background: #F5F5DC;" |
::::[[Metronidazole]] 2 g PO in a single dose
:::::[[Metronidazole]] 2 g PO in a single dose
::::::::''or''
:::::::::''or''
::::[[Tinidazole]] 2 g PO in a single dose
:::::[[Tinidazole]] 2 g PO in a single dose
::::::::'''PLUS'''
:::::::::'''PLUS'''
::::[[Azithromycin]] 1 g PO in a single dose
:::::[[Azithromycin]] 1 g PO in a single dose
|-
|-
|}
|}

Revision as of 14:00, 4 October 2016

Urinary Tract Infections Main Page

Sexually Transmitted Diseases Main Page

Urethritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Urethritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Urethritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Urethritis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onUrethritis medical therapy

CDC onUrethritis medical therapy

Urethritis medical therapyin the news

Blogs onUrethritis medical therapy

Directions to Hospitals Treating Urethritis

Risk calculators and risk factors for Urethritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2];Cafer Zorkun, M.D., Ph.D. [3];Sujit Routray, M.D. [4]

Overview

Once the diagnosis is confirmed the appropriate antibiotic regimen should started to reduce the risk of complications.[1]. The standard of choice is described below.

Medical Therapy

Antibiotic Therapy

Disease Treatment
Nongonococcal Urethritis Preferred:
Azithromycin 1 g PO in a single dose
OR
Doxycycline 100 mg PO bid for 7 days

Alternatives:

Erythromycin base 500 mg PO qid for 7 days
Erythromycin ethylsuccinate 800 mg PO qid for 7 days
Levofloxacin 500 mg PO qd for 7 days
Ofloxacin 300 mg PO bid for 7 days
Gonococcal Urethritis Preferred:
Ceftriaxone 250 mg IM in a single dose
PLUS
Azithromycin 1 g PO in a single dose

Alternative:

Cefixime 400 mg PO in a single dose
PLUS
Azithromycin 1 g PO in a single dose
Recurrent and Persistent Urethritis
Metronidazole 2 g PO in a single dose
or
Tinidazole 2 g PO in a single dose
PLUS
Azithromycin 1 g PO in a single dose

Follow-Up

  • Patients should be instructed to return for evaluation if symptoms persist or recur after completion of therapy.
  • Symptoms alone, without documentation of signs or laboratory evidence of urethral inflammation, are not a sufficient basis for re-treatment.
  • Providers should be alert to the possibility of chronic prostatitis/chronic pelvic pain syndrome in male patients experiencing persistent pain (perineal, penile, or pelvic), discomfort, irritative voiding symptoms, pain during or after ejaculation, or new-onset premature ejaculation lasting for > 3 months.
  • Unless a patient’s symptoms persist or therapeutic noncompliance or reinfection is suspected, a test-of-cure (i.e., repeat testing 3–4 weeks after completing therapy) is not recommended for persons with documented Chlamydia or gonococcal infections who have received treatment with recommended or alternative regimens. However, because men with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months after treatment, repeat testing for all men diagnosed with Chlamydia or Gonorrhea is recommended 3–6 months after treatment, regardless of whether patients believe that their sex partners were treated.
  • In individuals who have persistent symptoms after treatment without signs and symptoms of urethritis, the efficacy of extended-duration antimicrobials has not been demonstrated. Individuals who have persistent or recurrent urethritis can be retreated with the initial regimen if they did not comply with the treatment regimen or if they were re-exposed to an untreated sex partner. Persistent urethritis after doxycycline treatment might be caused by doxycycline-resistant U. urealyticum, M. genitalium, or T. vaginalis.

Treatment of Sexual Partners

  • All sex partners within the preceding 60 days should be referred for evaluation, testing, and empiric treatment with a drug regimen effective against Chlamydia.
  • A specific diagnosis might facilitate partner referral. Therefore, testing for gonorrhea and chlamydia is encouraged. Because a substantial proportion of female partners of males with non-chlamydial, non-gonococcal urethritis are infected with Chlamydia.
  • Partner treatment is recommended for males with non-gonococcal urethritis regardless of whether a specific etiology is identified.

References

  1. Stamm WE, Hicks CB, Martin DH, Leone P, Hook EW, Cooper RH, Cohen MS, Batteiger BE, Workowski K, McCormack WM (1995). "Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study". JAMA. 274 (7): 545–9. PMID 7629982.

Template:WH Template:WS